BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Parexel & Partex Unite Artificial Intelligence and Big Data to Speed Drug Discovery

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, a...

August 16, 2023 | News

Inmagene Initiates POC Study for Extended Half-Life OX40 mAb in Atopic Dermatitis

IMG-007 is a humanized IgG1 monoclonal antibody (mAb) that specifically binds to the OX40 receptor. Its Fc region has been bioengineered, resulting in...

August 16, 2023 | News

FDA Grants Priority Review for Cefepime-Taniborbactam to Treat cUTI

Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's N...

August 16, 2023 | News

OnCusp Therapeutics Gets FDA Nod for Phase 1 Trial of CUSP06 in Ovarian & Solid Tumors

"We are delighted to announce the IND approval for our flagship program, CUSP06, which has demonstrated excellent anti-tumor efficacy across diverse in&nbs...

August 16, 2023 | News

Kelun-Biotech's Phase III Trial of SKB264 Meets Endpoint in Advanced TNBC

Kelun-Biotech recently held an Independent Data Monitoring Committee (IDMC) meeting to review the interim analysis data of the Phase III clinical trial of ...

August 15, 2023 | News

Asieris Reports Successful Phase III Bridging Trial for Hexvix® in Bladder Cancer Diagnosis

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

August 14, 2023 | News

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

Under the collaboration, Boostimmune will have access to WuXi Biologics' integrated discovery services and extensive expertise in antibody discovery, lead ...

August 11, 2023 | News

First Patient Dosed in Phase III Prostate Cancer Imaging Study of TLX591-CDx in China

The Phase III Illuccix China study (ClinicalTrials.gov ID: NCT05847348) is a prospective, open-label, single-arm, multicenter study in Chinese...

August 11, 2023 | News

Clarity's theranostic prostate cancer trial advances to highest dose level

Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) ha...

August 11, 2023 | News

Positive Phase 3 Results for Fasedienol Nasal Spray in Social Anxiety Disorder by AffaMed's Partner Vistagen

First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reducti...

August 11, 2023 | News

Pharming Enrolls First Patient in Japanese APDS Treatment Trial

Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase ...

August 10, 2023 | News

First Patient Dosed in TLX101 Brain Cancer Study for Newly Diagnosed Glioblastoma

IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...

August 08, 2023 | News

Ascentage Pharma Gets FDA Clearance for Global Phase III Trial of Lisaftoclax in CLL/SLL Patients

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related...

August 07, 2023 | News

Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval

The Phase I MAD study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics ...

August 02, 2023 | News

Stay Connected